abs113.txt	rna-based		multi-gene	molecular	assays	are	available	and	widely	used	for	patientswith	er-positive/her2-negative	breast	cancers		however		rna-based	genomic	testscan	be	costly	and	are	not	available	in	many	countries		methods	for	inferringmolecular	subtype	from	histologic	images	may	identify	patients	most	likely	tobenefit	from	further	genomic	testing		to	identify	patients	who	could	benefit	frommolecular	testing	based	on	h&e	stained	histologic	images		we	developed	an	imageanalysis	approach	using	deep	learning		a	training	set	of	571	breast	tumors	wasused	to	create	image-based	classifiers	for	tumor	grade		er	status		pam50intrinsic	subtype		histologic	subtype		and	risk	of	recurrence	score	(ror-pt)		theresulting	classifiers	were	applied	to	an	independent	test	set	(n	=	288)		andaccuracy		sensitivity		and	specificity	of	each	was	assessed	on	the	test	set	histologic	image	analysis	with	deep	learning	distinguished	low-intermediate	vs	high	tumor	grade	(82%	accuracy)		er	status	(84%	accuracy)		basal-like	vs	non-basal-like	(77%	accuracy)		ductal	vs		lobular	(94%	accuracy)		and	high	vs	low-medium	ror-pt	score	(75%	accuracy)		sampling	considerations	in	the	trainingset	minimized	bias	in	the	test	set		incorrect	classification	of	er	status	wassignificantly	more	common	for	luminal	b	tumors		these	data	provide	proof	ofprinciple	that	molecular	marker	status		including	a	critical	clinical	biomarker(i	e			er	status)		can	be	predicted	with	accuracy	>75%	based	on	h&e	features	image-based	methods	could	be	promising	for	identifying	patients	with	a	greaterneed	for	further	genomic	testing		or	in	place	of	classically	scored	variablestypically	accomplished	using	human-based	scoring	
